Patents by Inventor Yingjun Zhang

Yingjun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250034169
    Abstract: A pyrimidopyridine compound, a pharmaceutical composition thereof, and a use thereof. Specifically, the present invention relates to a compound represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound represented by formula (I). The related compound and pharmaceutical composition thereof, as KRAS G12D inhibitors, can be used for preparing a drug for preventing or treating KRAS G12D-related diseases, especially for preparing a drug for preventing or treating cancer.
    Type: Application
    Filed: October 14, 2022
    Publication date: January 30, 2025
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Hongming XIE, Haiwang LIU, Yingjun ZHANG, Jinlong JIA, Xihui FENG
  • Patent number: 12209085
    Abstract: A RET inhibitor, a pharmaceutical composition thereof and uses thereof including a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Furthermore, a pharmaceutical composition including the compound, and uses of the compound and pharmaceutical composition thereof in the manufacture of a medicament for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: January 28, 2025
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Hongming Xie, Ming Luo, Jianli Wu, Yingjun Zhang, Yingchao Cheng
  • Publication number: 20240427421
    Abstract: Embodiments are directed to in-bed haptic systems including a pneumatic pad configured for placement between a user and a bed. The pneumatic pad can include an array of actuation cells, where each actuation cell in the array of actuation cells is configured to actuate in response to fluid being introduced into the actuation cell. The system can include an input device that includes a touch sensitive display and is configured to display a set of haptic sequences that can be applied to the array of actuation cells in a user interface of the input device and receive an input at the touch sensitive display of a selected haptic sequence. The system can include a control system that receives an indication of the selected haptic sequence and actuates actuation cells of the array of actuation cells using the selected haptic sequence and the pressure measurements.
    Type: Application
    Filed: August 31, 2022
    Publication date: December 26, 2024
    Inventors: Wegene H. Tadele, Yingjun Zhang, Siddharth Nangia
  • Patent number: 12128044
    Abstract: A fused tricyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the present invention relates to a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variable is as defined in the specification. The present invention also relates to the use of a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: October 29, 2024
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jianzhou Huang, Qingyun Ren, Jinfeng Xiong, Yang Liu, Xinchang Liu, Siegfried Goldmann, Yingjun Zhang, Yifeng Wang, Weishun Liu, Fangcai Yu
  • Publication number: 20240317681
    Abstract: A pyrrolidine amide derivative salt and the use thereof. Further, a pharmaceutical composition containing the salt, and the use of the salt or the pharmaceutical composition containing the salt in the preparation of a drug for preventing, treating or alleviating diseases adjusted by means of MAO-B, wherein the diseases include neurodegenerative diseases, in particular Parkinson's disease.
    Type: Application
    Filed: July 6, 2021
    Publication date: September 26, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chuanfei JIN, Kangzhi CHEN, Yingjun ZHANG
  • Publication number: 20240176914
    Abstract: A data processing method includes obtaining target constant data to be accessed in first code, where a length of the target constant data is greater than a preset threshold; and inserting a plurality of data transfer instructions into the first code based on a location of an objective function in the first code to obtain second code, where the objective function is a function that needs to access the target constant data, each data transfer instruction of the plurality of data transfer instructions includes a part of data in the target constant data, the plurality of data transfer instructions are used to write the target constant data into a register, and the second code is labeled as being stored into a storage area not having a read permission.
    Type: Application
    Filed: February 8, 2024
    Publication date: May 30, 2024
    Inventors: Kun Li, Yingjun Zhang
  • Publication number: 20240025905
    Abstract: Salts of dihydropyrimidine derivatives, complexes and uses thereof in medicine, and complexes and pharmaceutical compositions thereof. The uses of the addition salts, the complexes or the pharmaceutical compositions in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis B virus (HBV) infection.
    Type: Application
    Filed: November 30, 2021
    Publication date: January 25, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qingyun REN, Xinchang LIU, Yingjun ZHANG, Guanghua YAN
  • Publication number: 20240010643
    Abstract: A preparation method of substituted pyrimidine piperazine compounds, as well as intermediate compounds used in the method. The preparation method has the advantages of cheap and easily available raw materials, mild conditions, short reaction time, safety and controllability, high total yield, which is especially suitable for industrial production.
    Type: Application
    Filed: September 16, 2021
    Publication date: January 11, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chuanfei JIN, Haiping LIANG, Tengfei XU, Yingjun ZHANG
  • Publication number: 20230281304
    Abstract: This application discloses a method for switching an execution environment and a related device thereof, to effectively prevent a hacker from maliciously accessing a TEE through ATF. The method in this application includes: After writing a first virtual address into a return address register of the TEE, the ATF determines whether the first virtual address is within a valid address range, and switches to the TEE based on the first virtual address only when determining that the first virtual address is within the valid address range.
    Type: Application
    Filed: May 12, 2023
    Publication date: September 7, 2023
    Inventors: Yingjun ZHANG, Ji WANG, Yingliang YAO
  • Publication number: 20230121086
    Abstract: A ROR?t inhibitor as well as a preparation method thereof and uses thereof, and a pharmaceutical composition including the compound, a method for preparing the pharmaceutical composition, and use of the compound or the pharmaceutical composition in the treatment or prevention of ROR?t-mediated cancer, inflammation, or autoimmune diseases in mammals, especially humans.
    Type: Application
    Filed: December 31, 2020
    Publication date: April 20, 2023
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Bing LIU, Yingjun ZHANG, Wei PAN, Feng WANG, Xuke LI, Wei HE, Jiuzhong HUANG
  • Publication number: 20230067159
    Abstract: An ROR?t inhibitor, a preparation method thereof and uses thereof. The invention also relates to a pharmaceutical composition of the compound, a method for preparing the pharmaceutical composition, and use of the compound or the pharmaceutical composition in treating or preventing cancer, inflammation, or autoimmune diseases mediated by ROR?t in mammals.
    Type: Application
    Filed: December 31, 2020
    Publication date: March 2, 2023
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Bing LIU, Wei PAN, Feng WANG, Wei HE
  • Patent number: 11447498
    Abstract: A fused tetracyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. A compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B, wherein each variable is as defined in the specification.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: September 20, 2022
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jianzhou Huang, Qingyun Ren, Jinfeng Xiong, Yang Liu, Yingjun Zhang
  • Publication number: 20220273760
    Abstract: Pharmaceuticals, and specifically a Teixobactin analogue and use thereof. A pharmaceutical composition having the compound and use of the compound and the pharmaceutical composition thereof inhibits the growth and/or reproduction of Gram-positive bacteria or Mycobacterium tuberculosis.
    Type: Application
    Filed: July 23, 2020
    Publication date: September 1, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qingyun REN, Zhimin XIONG, Yingjun ZHANG, Xuechen LI, Xianwu FU, Ali HUANG, Huichao LUO
  • Publication number: 20220267346
    Abstract: Thienopyrimidine derivative having stereo configurations and use thereof in medicine. Also included are pharmaceutical compositions of the compounds. The compounds or pharmaceutical compositions may be used to inhibit acetyl-CoA carboxylase (ACC). A method for preparing the compounds and the pharmaceutical compositions, and use thereof in treatment or prevention of diseases associated with ACC regulation of mammals, in particular, humans.
    Type: Application
    Filed: July 2, 2019
    Publication date: August 25, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng GU, Wanjun TANG, Xinye YANG, Xuli WANG, Weihui YUAN, Yunzeng CUI, Wen YANG, Jianyu LIU, Yingjun ZHANG
  • Patent number: 11396495
    Abstract: An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 26, 2022
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng Gu, Jianhao Li, Zheng Li, Weihua Wang, Haoxiong Qin, Xuli Wang, Jianyu Liu, Yingjun Zhang
  • Publication number: 20220211665
    Abstract: A pyrrole amide compound, a pharmaceutical composition thereof and use thereof. The compound or the pharmaceutical composition can be used as a mineralocorticoid receptor antagonist.
    Type: Application
    Filed: October 21, 2020
    Publication date: July 7, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiancheng WANG, Xiaojun WANG, Yinglin ZUO, Yingxun ZHANG, Yingjun ZHANG, Bo CHI, Wei HAN, Xiaohong DING, Junnan ZENG
  • Publication number: 20220194951
    Abstract: A dihydropyrimidine compound and application thereof as a drug, in particular, application as a drug for treating and preventing hepatitis B. Specifically, a compound represented by general formula (I) or (Ia) or a stereoisomer, a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein variables are as defined in the description. Use of the compound represented by general formula (I) or (Ia) or the stereoisomer, the tautomer, the oxynitride, the solvate, the metabolite, or the pharmaceutically acceptable salt thereof as a drug, in particular use as a drug for treating and preventing hepatitis B.
    Type: Application
    Filed: April 29, 2020
    Publication date: June 23, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qingyun REN, Yingjun ZHANG, Xinchang LIU, Siegfried GOLDMANN, Guanghua YAN, Meng WANG, Douxing LEI, Feng LI
  • Publication number: 20220135557
    Abstract: A RET inhibitor, a pharmaceutical composition thereof and uses thereof including a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Furthermore, a pharmaceutical composition including the compound, and uses of the compound and pharmaceutical composition thereof in the manufacture of a medicament for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.
    Type: Application
    Filed: December 6, 2019
    Publication date: May 5, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Hongming XIE, Ming LUO, Jianli WU, Yingjun ZHANG, Yingchao CHENG
  • Publication number: 20220119382
    Abstract: A RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, the present invention provides a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The invention also relates to a pharmaceutical composition including the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.
    Type: Application
    Filed: December 6, 2019
    Publication date: April 21, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Hongming XIE, Ming LUO, Jianli WU, Yingjun ZHANG, Yingchao CHENG
  • Patent number: 11285153
    Abstract: A substituted pyrimidine piperazine compound and uses thereof, and a pharmaceutical composition containing the compound and uses thereof. Wherein the compound has Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted pyrimidine piperazine compound and the pharmaceutical composition containing the compound can be used to inhibit 5-hydroxytryptamine reuptake and/or activate the 5-HT1A receptors. Also, a method of preparing such compounds and pharmaceutical compositions, and uses thereof in the treatment of central nervous system dysfunction.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 29, 2022
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chuanfei Jin, Wenhe Zhong, Haiping Liang, Yingjun Zhang